Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Enoxaparin for VTE Prophylaxis in Bariatric Surgery
NCT06689241Recruiting
- Sponsor
- Alexandria University
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Alexandria University. Primary endpoint: Incidence of thromboembolic events (deep vein thrombosis, pulmonary thromboembolism, mesenteric vascular occlusion) at 3 months. Started Oct 2024; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06689241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689241.